Hawaii House Bill HB1133

Hawaii 2026 Regular Session

• Introduced: 1/23/25
• Refer: 1/23/25

Caption

Relating To The Uniform Controlled Substance Act.

Impact

If passed, the modifications introduced by HB1133 will lead to changes in how certain drugs, particularly newer substances and variants, are classified and regulated under state law. By aligning more closely with federal standards, the bill is expected to simplify legal definitions and provide a more comprehensive approach to controlling drug substances within the state. The anticipated result is improved enforcement capabilities for law enforcement agencies and clearer guidelines for healthcare providers in terms of prescribing and managing controlled substances.

Summary

House Bill 1133 seeks to amend the Uniform Controlled Substances Act in Hawaii, particularly updating chapter 329 of the Hawaii Revised Statutes. This bill aims to ensure that state law is consistent with recent amendments to the Federal Controlled Substances Act. The legislative intent is to clarify and streamline the regulation of controlled substances in Hawaii, making it easier for law enforcement and health officials to address medication safety and illicit drug use. Through this update, the bill intends to enhance public health and safety by regulating new substances that may pose threats to public safety.

Contention

While the bill is primarily designed to improve public safety through better regulation, there may be points of contention surrounding the implications for pain management and access to certain medications. Some advocates for patients may express concerns that tighter regulations could inadvertently hinder access to necessary medications for individuals with chronic pain or other health conditions. Balancing the need for stringent controls while ensuring that patients continue to receive appropriate care is likely to be a topic of debate among legislators and community stakeholders as the bill progresses.